157 related articles for article (PubMed ID: 22222334)
1. The efficacy of abraxane on osteosarcoma xenografts in nude mice and expression of secreted protein, acidic and rich in cysteine.
Yang Y; Niu X; Zhang Q; Hao L; Ding Y; Xu H
Am J Med Sci; 2012 Sep; 344(3):199-205. PubMed ID: 22222334
[TBL] [Abstract][Full Text] [Related]
2. Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer.
Shao H; Tang H; Salavaggione OE; Yu C; Hylander B; Tan W; Repasky E; Adjei AA; Dy GK
J Thorac Oncol; 2011 Jun; 6(6):998-1005. PubMed ID: 21532503
[TBL] [Abstract][Full Text] [Related]
3. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.
Desai NP; Trieu V; Hwang LY; Wu R; Soon-Shiong P; Gradishar WJ
Anticancer Drugs; 2008 Oct; 19(9):899-909. PubMed ID: 18766004
[TBL] [Abstract][Full Text] [Related]
4. Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP).
Houghton PJ; Kurmasheva RT; Kolb EA; Gorlick R; Maris JM; Wu J; Tong Z; Arnold MA; Chatterjee M; Williams TM; Smith MA
Pediatr Blood Cancer; 2015 Jul; 62(7):1214-21. PubMed ID: 25809532
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma.
Wagner LM; Yin H; Eaves D; Currier M; Cripe TP
Pediatr Blood Cancer; 2014 Nov; 61(11):2096-8. PubMed ID: 24753077
[TBL] [Abstract][Full Text] [Related]
6. Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer.
Demeure MJ; Stephan E; Sinari S; Mount D; Gately S; Gonzales P; Hostetter G; Komorowski R; Kiefer J; Grant CS; Han H; Von Hoff DD; Bussey KJ
Ann Surg; 2012 Jan; 255(1):140-6. PubMed ID: 22156929
[TBL] [Abstract][Full Text] [Related]
7. SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas.
Pascual-Pasto G; Castillo-Ecija H; Unceta N; Aschero R; Resa-Pares C; Gómez-Caballero A; Vila-Ubach M; Muñoz-Aznar O; Suñol M; Burgueño V; Gomez-Gonzalez S; Sosnik A; Ibarra M; Schaiquevich P; de Álava E; Tirado OM; Mora J; Carcaboso AM
J Control Release; 2022 Feb; 342():81-92. PubMed ID: 34974029
[TBL] [Abstract][Full Text] [Related]
8. Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors.
Zhang L; Marrano P; Kumar S; Leadley M; Elias E; Thorner P; Baruchel S
Clin Cancer Res; 2013 Nov; 19(21):5972-83. PubMed ID: 23989978
[TBL] [Abstract][Full Text] [Related]
9. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP).
Vanhoefer U; Cao S; Harstrick A; Seeber S; Rustum YM
Ann Oncol; 1997 Dec; 8(12):1221-8. PubMed ID: 9496387
[TBL] [Abstract][Full Text] [Related]
10. SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts.
Kim H; Samuel S; Lopez-Casas P; Grizzle W; Hidalgo M; Kovar J; Oelschlager D; Zinn K; Warram J; Buchsbaum D
Mol Cancer Ther; 2016 Apr; 15(4):680-8. PubMed ID: 26832793
[TBL] [Abstract][Full Text] [Related]
11. ABCB1-overexpressing MG63/DOX cell xenograft model: maintain the MDR phenotype in vivo.
Zhou Z; Wan L; Han Y; Meng X; Yang Q; Li Y; Yu Q; Shen Z; Guo C
Pharm Biol; 2013 Aug; 51(8):968-73. PubMed ID: 23735077
[TBL] [Abstract][Full Text] [Related]
12. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.
Neesse A; Frese KK; Chan DS; Bapiro TE; Howat WJ; Richards FM; Ellenrieder V; Jodrell DI; Tuveson DA
Gut; 2014 Jun; 63(6):974-83. PubMed ID: 24067278
[TBL] [Abstract][Full Text] [Related]
13. FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells.
Imai T; Adachi S; Nishijo K; Ohgushi M; Okada M; Yasumi T; Watanabe K; Nishikomori R; Nakayama T; Yonehara S; Toguchida J; Nakahata T
Oncogene; 2003 Dec; 22(58):9231-42. PubMed ID: 14647441
[TBL] [Abstract][Full Text] [Related]
14. X609, a novel manassantin A derivative, exhibits antitumor activity in MG-63 human osteosarcoma cells in vitro and in vivo.
Li J; Zhao K; Wang F; Cai J; Li Z; Zou L
Mol Med Rep; 2015 Aug; 12(2):3115-20. PubMed ID: 25954853
[TBL] [Abstract][Full Text] [Related]
15. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
16. RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines.
Yang C; Hornicek FJ; Wood KB; Schwab JH; Mankin H; Duan Z
Cancer Chemother Pharmacol; 2009 Aug; 64(3):607-14. PubMed ID: 19125251
[TBL] [Abstract][Full Text] [Related]
17. Antineoplastic effect of calycosin on osteosarcoma through inducing apoptosis showing in vitro and in vivo investigations.
Qiu R; Ma G; Zheng C; Qiu X; Li X; Li X; Mo J; Li Z; Liu Y; Mo L; Bi G; Ye Y
Exp Mol Pathol; 2014 Aug; 97(1):17-22. PubMed ID: 24797937
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib sensitizes human osteosarcoma cells to adriamycin-induced apoptosis through ROS-dependent activation of p-eIF2α/ATF4/CHOP axis.
Xian M; Cao H; Cao J; Shao X; Zhu D; Zhang N; Huang P; Li W; Yang B; Ying M; He Q
Int J Cancer; 2017 Sep; 141(5):1029-1041. PubMed ID: 28524233
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
[TBL] [Abstract][Full Text] [Related]
20. Apigenin induces apoptosis through mitochondrial dysfunction in U-2 OS human osteosarcoma cells and inhibits osteosarcoma xenograft tumor growth in vivo.
Lin CC; Chuang YJ; Yu CC; Yang JS; Lu CC; Chiang JH; Lin JP; Tang NY; Huang AC; Chung JG
J Agric Food Chem; 2012 Nov; 60(45):11395-402. PubMed ID: 23066961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
